inhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Abstract
Isoniazid (isonicotinic acid hydrazide, INH) is one of the most widely used antituberculosis drugs, yet its precise target of action on Mycobacterium tuberculosis is unknown. A missense mutation within the mycobacterial inhA gene was shown to confer resistance to both INH and ethionamide (ETH) in M. smegmatis and in M. bovis . The wild-type inhA gene also conferred INH and ETH resistance when transferred on a multicopy plasmid vector to M. smegmatis and M. bovis BCG. The InhA protein shows significant sequence conservation with the Escherichia coli enzyme EnvM, and cell-free assays indicate that it may be involved in mycolic acid biosynthesis. These results suggest that InhA is likely a primary target of action for INH and ETH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhA was identified as the target of activated INH by an M. smegmatis missense mutation that conferred co-resistance to both INH and Ethionamide (ETH) (129).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [129]
Citations
Cites
Introduction to Protein Structure
Branden, C. I., & Tooze, J. (2012) · Garland Science eBooks · doi:10.1201/9781136969898 · Cited by 2,382
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
Telenti, A., Imboden, P., Marchesi, F., Matter, L., Schopfer, K., Bodmer, T., Lowrie, D., Colston, M. J., & Cole, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)90417-f · Cited by 1,337
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
Zhang, Y., Heym, B., Allen, B., Young, D., & Cole, S. (1992) · Nature · doi:10.1038/358591a0 · Cited by 1,299
Snapper, S. B., Melton, R. E., Mustafa, S., Kieser, T., & Jr, W. R. J. (1990) · Molecular Microbiology · doi:10.1111/j.1365-2958.1990.tb02040.x · Cited by 1,237
Self-citationThe Emergence of Drug-Resistant Tuberculosis in New York City
Frieden, T. R., Sterling, T., Pablos-Mendez, A., Kilburn, J. O., Cauthen, G. M., & Dooley, S. W. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280801 · Cited by 939
Tuberculosis in developing countries: burden, intervention and cost.
Murray, C. J. L., Styblo, K., & Rouillon, A. (1990) · PubMed · Cited by 571
[25] Genetic systems for mycobacteria
Jacobs, W. R., Kalpana, G. V., Cirillo, J. D., Pascopella, L., Snapper, S. B., Udani, R. A., Jones, W., Barletta, R. G., & Bloom, B. R. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)04027-l · Cited by 433
Self-citationSnider, D. E., & Roper, W. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203053261011 · Cited by 382
Combs, D. L., O'Brien, R. J., & Geiter, L. J. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-397 · Cited by 315
Takayama, K., Wang, L., & David, H. L. (1972) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.2.1.29 · Cited by 292
Research works printed but not linked: 8
- BEGGS, W.H., AM REV RESPIR DIS 102: 94 (1969).
- GOPINATHAN, K.P., SPECIFICITY OF ISONIAZID ACTION AGAINST MYCOBACTERIA AND A POSSIBLE MECHANISM FOR THE DEVELOPMENT OF DRUG-RESISTANCE, CURRENT SCIENCE 50: 216 (1981).
- GRUMBACH, F, REVUE DE TUBERCULOSE ET DE PNEUMOLOGIE 25: 1365 (1961).
- MIDDLEBROOK, G, AMERICAN REVIEW OF TUBERCULOSIS 65: 765 (1952).
- MURRAY, C. J. L., BULLETIN OF THE INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE 65: 6 (1990).
- Murray, C., Disease Control Priorities in Developing Countries: 233 (1993).
- OFFE, H.A., ZEITSCHRIFT FUR NATURFORSCHUNG 76: 462 (1952).
- PANSY, F, INVITRO STUDIES ON ISONICOTINIC ACID HYDRAZIDE, AMERICAN REVIEW OF TUBERCULOSIS 65: 761 (1952).
Cited by
Items 301–400 of 1,000
Evidence-Based Annotation of the Malaria Parasite's Genome Using Comparative Expression Profiling
Zhou, Y., Ramachandran, V., Kumar, K. A., Westenberger, S. J., Refour, P., Zhou, B., Li, F., Young, J. A., Chen, K., Plouffe, D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001570 · Cited by 80
“The group includes PF11_0256, the pyruvate dehydrogenase alpha subunit 1; PF14_0441, the pyruvate dehydrogenase E1 beta subunit; PF08_0066, dihydrolipoamide dehydrogenase; PF10_0407, dihydrolipoamide acetyltransferase and PFF0730c, enoyl-acyl carrier reductase (ENR, the presumed target of the Mycobacterium tuberculosi…”
BackgroundBaker, L. V., Brown, T., Maxwell, O., Gibson, A. L., Fang, Z., Yates, M. D., & Drobniewski, F. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1455-1464.2005 · Cited by 86
“smegmatis, isoniazid resistance results from a single amino acid substitution in inhA, a gene encoding an enoyl acyl carrier protein reductase involved in mycolic acid synthesis (3).”
BackgroundRamos, P. I. P., Porto, D. F. D., Lanzarotti, E., Sosa, E. J., Burguener, G., Pardo, A., Klein, C. C., Sagot, M., de Vasconcelos, A. T. R., Gales, A. C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28916-7 · Cited by 86
Mycobacterium Tuberculosis: Drug Resistance and Future Perspectives
Riccardi, G., Pasca, M. R., & Buroni, S. (2009) · Future Microbiology · doi:10.2217/fmb.09.20 · Cited by 86
Khan, S., Nagarajan, S. N., Parikh, A., Samantaray, S., Singh, A., Kumar, D., Roy, R. P., Bhatt, A., & Nandicoori, V. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.143131 · Cited by 76
Marttila, H., Soini, H., Huovinen, P., & Viljanen, M. K. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.9.2187 · Cited by 76
“The segment contains the region encoding amino acids Ser-94 and Ile-95 that have been associated with resistance (2, 13).”
BackgroundNachamkin, I., Kang, C., & Weinstein, M. P. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.5.894 · Cited by 76
“for mutations in inhA [2].”
BackgroundInfluentialBanerjee, A., Sugantino, M., Sacchettini, J. C., & Jacobs, W. R. (1998) · Microbiology · doi:10.1099/00221287-144-10-2697 · Cited by 96
Self-citationPeters, S., Muñoz, M., Yerly, S., Sánchez-Merino, V., López‐Galíndez, C., Perrin, L. H., Larder, B. A., Cmarko, D., Fakan, S., Meylan, P. R., et al. (2001) · Journal of Virology · doi:10.1128/jvi.75.20.9644-9653.2001 · Cited by 83
“Well-known examples are the resistance of Mycobacterium tuberculosis to isoniazid through up-promoter mutations in inhA that increase the enoyl reductase drug target, resistance in the parasite Leishmania donovani to methotrexate through dihydrofolate reductase target amplification, and resistance in Candida glabrata…”
BackgroundPaul, D., Chakraborty, R., & Mandal, S. M. (2019) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2019.02.083 · Cited by 91
Drug resistance, fitness and compensatory mutations in Mycobacterium tuberculosis
Emane, A. K. A., Guo, X., Takiff, H. E., & Liu, S. (2021) · Tuberculosis · doi:10.1016/j.tube.2021.102091 · Cited by 86
A silent mutation in mabA confers isoniazid resistance on M ycobacterium tuberculosis
Ando, H., Miyoshi‐Akiyama, T., Watanabe, S., & Kirikae, T. (2013) · Molecular Microbiology · doi:10.1111/mmi.12476 · Cited by 91
“…in the region upstream of the mabA–inhA operon was shown to enhance inhA transcription in Mtb (Vilcheze et al., 2006), with cis-elements, including a pro- moter region upstream of the mabA–inhA operon, required for the (over)expression of inhA (Banerjee et al., 1994; Vilcheze et al., 2006).”
BackgroundInfluentialFreundlich, J. S., Wang, F., Tsai, H.-C., Kuo, M. R., Shieh, H.-M., Anderson, J. W., Nkrumah, L. J., Valderramos, J., Yu, M., Kumar, T. R. S., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701813200 · Cited by 76
Self-citationCoxon, G. D., Craig, D., Corrales, R. M., Vialla, E., Gannoun-Zaki, L., & Kremer, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053162 · Cited by 83
“Several successful antitubercular drugs, including isoniazid (INH) and ethionamide (ETH), inhibit enzymes required for mycolic acid synthesis [5,8,9].”
BackgroundMechanisms of Bacterial Resistance to Antibiotics and Biocides
Russell, A. D. (1998) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)70036-5 · Cited by 86
Nishida, C. R., & de Montellano, P. R. O. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.09.015 · Cited by 77
“Gene array studies have shown that both INH and ETA induce similar patterns of protein expression [13], and mutations in the InhA gene give rise to resistance to both INH and ETA [14,15].”
BackgroundThe complex architecture of mycobacterial promoters
Newton-Foot, M., & van Pittius, N. C. G. (2012) · Tuberculosis · doi:10.1016/j.tube.2012.08.003 · Cited by 97
Zimhony, O., Vilchèze, C., & Jacobs, W. R. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.13.4051-4055.2004 · Cited by 92
Self-citationWang, R., Prince, J. T., & Marcotte, E. M. (2005) · Genome Research · doi:10.1101/gr.3994105 · Cited by 86
“2B): the genes that synthesize mycolic acid, the main component of the cell wall in mycobacteria and the end product in the metabolic pathway of InhA, which is the primary target of the mycobacterial drug isoniazid (Banerjee et al. 1994).”
BackgroundSchöneborn, H., Bulle, J. M. G., & von Kiedrowski, G. (2001) · ChemBioChem · doi:10.1002/1439-7633(20011203)2:12<915::aid-cbic915>3.0.co;2-m · Cited by 21
Kibiki, G. S., Mulder, B., Dolmans, W. M. V., de Beer, J. L., Boeree, M. J., Sam, N., van Soolingen, D., Sola, C., & van der Zanden, A. G. (2007) · BMC Microbiology · doi:10.1186/1471-2180-7-51 · Cited by 73
Veyron-Churlet, R., Molle, V., Taylor, R. C., Brown, A. K., Besra, G. S., Zanella-Cléon, I., Fütterer, K., & Kremer, L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806537200 · Cited by 73
Epidemiology of Isoniazid Resistance Mutations and Their Effect on Tuberculosis Treatment Outcomes
Huyen, M. N. T., Cobelens, F. G. J., Buu, T. N., Lan, N. T. N., Dung, N. H., Kremer, K., Tiemersma, E. W., & van Soolingen, D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00077-13 · Cited by 84
Chapter 6: Mycobacterium: Isolation, Maintenance, Transformation, and Mutant Selection
Connell, N. D. (1995) · Methods in cell biology · doi:10.1016/s0091-679x(08)61848-8 · Cited by 77
Mechanisms involved in the intrinsic isoniazid resistance of Mycobacterium avium
Mdluli, K. E., Swanson, J., Fischer, E. R., Lee, R. E., Jr., & Barry, C. E. (1998) · Molecular Microbiology · doi:10.1046/j.1365-2958.1998.00774.x · Cited by 74
Grzegorzewicz, A. E., Eynard, N., Quémard, A., North, E. J., Margolis, A., Lindenberger, J. J., Jones, V. M., Korduláková, J., Brennan, P. J., Lee, R. E., Jr., et al. (2014) · ACS Infectious Diseases · doi:10.1021/id500032q · Cited by 72
Veyron‐Churlet, R., Bigot, S., Guerrini, O., Verdoux, S., Malaga, W., Daffé, M., & Zerbib, D. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.09.016 · Cited by 82
Wang, F., Jain, P., Gülten, G., Liu, Z., Feng, Y., Ganesula, K., Motiwala, A. S., Ioerger, T. R., Alland, D., Vilchèze, C., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00453-10 · Cited by 72
“Even though DHFR has been shown to bind an INH-NADP adduct in vitro, this phenomenon is not sufficient to confer INH or ETH resistance in mycobacterial cells.”
BackgroundSelf-citationLiu, J., Shi, W., Zhang, S., Cassell, G., Maslov, D. A., Shur, K. V., Bekker, O. B., Даниленко, В. Н., Hao, X., & Zhang, Y. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00216 · Cited by 75
“, 1992; Zhang and Yew, 2009) or inhA (Banerjee et al., 1994).”
Mycobacterium tuberculosis: drug-resistance mechanisms
Cole, S. T. (1994) · Trends in Microbiology · doi:10.1016/0966-842x(94)90621-1 · Cited by 73
3 Persisting problems in tuberculosis
McKinney, J. D., Jacobs, W. R., & Bloom, B. R. (1998) · Biomedical research reports · doi:10.1016/s1874-5326(07)80027-5 · Cited by 82
Self-citationThe reductase steps of the type II fatty acid synthase as antimicrobial targets
Zhang, Y., Lu, Y., & Rock, C. O. (2004) · Lipids · doi:10.1007/s11745-004-1330-3 · Cited by 71
“InhA is the enoyl-ACP reductase in Mycobacterium tuberculosis and the primary target of the antituberculosis drug isoniazid (INH) ( 9 ,21).”
BackgroundInfluentialMycobacterium tuberculosis efpA encodes an efflux protein of the QacA transporter family
Doran, J. L., Pang, Y., Mdluli, K. E., Moran, A. J., Victor, T. C., Stokes, R. W., Mahenthiralingam, E., Kreiswirth, B. N., BUTT, J. L., Baron, G. S., et al. (1997) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.4.1.23-32.1997 · Cited by 71
Ribosomal mutations promote the evolution of antibiotic resistance in a multidrug environment
Gomez, J. E., Kaufmann-Malaga, B., Wivagg, C. N., Kim, P. B., Silvis, M. R., Renedo, N., Ioerger, T. R., Ahmad, R., Livny, J., Fishbein, S. R. S., et al. (2017) · eLife · doi:10.7554/elife.20420 · Cited by 79
“…in a variety of ways, including altering the target to prevent antibiotic binding (Musser, 1995; Jacoby, 2005), increasing target expression (Banerjee et al., 1994; Rouse et al., 1995), decreasing intracellular drug concen- tration via enhanced efflux or reduced permeability (Fernández and…”
BackgroundPatil, P. S., Kasare, S. L., Haval, N. B., Khedkar, V. M., Dixit, P. P., Rekha, E. M., Sriram, D., & Haval, K. P. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127434 · Cited by 73
Maccari, R., Ottanà, R., Monforte, F., & Vigorita, M. G. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.294-299.2002 · Cited by 70
“both INH and ethionamide, with inhA being a primary target of action of both INH and ethionamide (1, 13, 23, 24).”
BackgroundHuyen, M. N. T., Tiemersma, E. W., Lan, N. T. S., Cobelens, F. G. J., Dung, N. H., Sy, D. N., Buu, T. N., Kremer, K., Hằng, P. T., Caws, M., et al. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-149 · Cited by 70
“Mutations conferring resistance to INH are located at several genomic loci (katG, inhA and kasA) [10-14].”
Herrera, L., Molina, T., Sáiz, P. A., Sáez-Nieto, J. A., & Jiménez, M. S. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.144-147.2005 · Cited by 70
“, the katG gene, encoding catalase-peroxidase (31), and the mabA-inhA regulon (4), encoding a target of activated prodrug, enoyl-acyl carrier protein reductase (1–3, 11, 13, 15, 17, 21, 27).”
BackgroundHepatoprotective effects of natural drugs: Current trends, scope, relevance and future perspectives
Datta, S., Aggarwal, D., Sehrawat, N., Yadav, M. K., Sharma, V., Sharma, A. K., Zghair, A. N., Dhama, K., Sharma, A., Kumar, V., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155100 · Cited by 81
inhA promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa?
Müller, B., Streicher, E. M., Hoek, K. G. P., Tait, M., Trollip, A. P., Bosman, M. E., Coetzee, G. J., Chabula-Nxiweni, E. M., Hoosain, E., van Pittius, N. C. G., et al. (2011) · PubMed · Cited by 69
Resistance to Antitubercular Drugs
Basso, L. A., & Blanchard, J. S. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4897-3_7 · Cited by 84
Ruíz, M., Torres, M. J., Llanos, A. C., Arroyo, A., Palomares, J. C., & Aznar, J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1585-1589.2004 · Cited by 71
“More than 96% of rifampinresistant strains have mutations in an 81-bp “core region” of the rpoB gene, which encodes the subunit of the RNA polymerase (10, 21), and the majority of isoniazid-resistant strains have been found to contain mutations in codon 315 of the katG gene, which encodes the catalase-peroxidase (30),…”
BackgroundBakonytė, D., Baranauskaite, A., Cicenaite, J., Sosnovskaja, A., & Stakėnas, P. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.6.2009-2011.2003 · Cited by 92
“Mutations both at the Ser315 codon of katG, encoding catalase-peroxidase, the enzyme oxidizing INH (4), and at the regulatory region of the mabA-inhA operon, encoding a target of activated prodrug, enoyl-acyl carrier protein reductase (2), occur most frequently in INH-resistant isolates (9, 11, 13).”
BackgroundBailey, T. L., Baker, M. E., & Elkan, C. (1997) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)00013-7 · Cited by 84
Isoniazid Bactericidal Activity Involves Electron Transport Chain Perturbation
Zeng, S., Soetaert, K., Ravon, F., Vandeput, M., Bald, D., Kauffmann, J., Mathys, V., Wattiez, R., & Fontaine, V. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01841-18 · Cited by 72
Metabolic Versatility of Mycobacterium tuberculosis during Infection and Dormancy
Chang, D. P. S., & Guan, X. L. (2021) · Metabolites · doi:10.3390/metabo11020088 · Cited by 82
Lavender, C. J., Globan, M., Sievers, A. S., Billman‐Jacobe, H., & Fyfe, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.10.4068-4074.2005 · Cited by 70
“While the absence of mutations in this region in the INHs control strains indicates that fabG1-inhA regulatory region mutations may play a role in INH resistance, the effect(s) of these mutations on FabG1 and/or InhA protein synthesis and in turn the mechanism of resistance conferred by these mutations are yet to be e…”
BackgroundInfluentialde Oliveira, J. S., Sousa, E. H. S., Basso, L. A., Palaci, M., Dietze, R., Santos, D. S., & Moreira, �. S. (2004) · Chemical Communications · doi:10.1039/b313592f · Cited by 68
THPP target assignment reveals EchA6 as an essential fatty acid shuttle in mycobacteria
Cox, J. A. G., Abrahams, K. A., Alemparte, C., Ghidelli, S., Rullás, J., Angulo‐Barturen, Í., Singh, A., Gurcha, S. S., Nataraj, V., Bethell, S., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2015.6 · Cited by 73
The Biosynthesis of Mycolic Acids in Mycobacterium tuberculosis
Yuan, Y., Mead, D., Schroeder, B. G., Zhu, Y., & Barry, C. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.33.21282 · Cited by 68
Laboratory diagnostic aspects of drug resistant tuberculosis
Linda, M. P. (2004) · Frontiers in bioscience · doi:10.2741/1290 · Cited by 77
de Oliveira, J. S., Pereira, J. H., Canduri, F., Rodrigues, N. C., de Souza, O. N., de Azevedo, W. F., Basso, L. A., & Santos, D. S. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.03.055 · Cited by 86
Schiebel, J., Chang, A. T., Shah, S., Lü, Y., Liu, L., Pan, P., Hirschbeck, M. W., Tareilus, M., Eltschkner, S., Yu, W., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.532804 · Cited by 67
Jankute, M., Grover, S., Rana, A. K., & Besra, G. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.123 · Cited by 79
“tubercu‐ losis cell wall [11,12].”
Żaczek, A., Brzostek, A. M., AUGUSTYNOWICZ-KOPEĆ, E. M., Zwolska, Z., & Dziadek, J. (2009) · BMC Microbiology · doi:10.1186/1471-2180-9-10 · Cited by 77
“The drug resistance of M. tuberculosis can be also connected to the overproduction of a drug target due to accumulation of point mutations in a promoter region [ 40- 42 ].”
BackgroundPlatensimycin Activity against Mycobacterial β-Ketoacyl-ACP Synthases
Brown, A. K., Taylor, R. C., Bhatt, A., Fütterer, K., & Besra, G. S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006306 · Cited by 73
“KasA and KasB are two distinct ketosynthases that are part of a core FAS-II complex which also includes a keto-reductase (FabG1, MabA), a multicomponent dehydratase (Rv0636+ Rv0635 or Rv0637) and an enoyl reductase (InhA) [8,9,10,11, 12,13,14,15,16].”
BackgroundBatt, S. M., Cacho, M., Castro‐Pichel, J., Stubbs, C. J., Peral, L. V.-G. D., Pérez‐Herrán, E., Dhar, N., Mouzon, B., Rees, M., Hutchinson, J. P., et al. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00065 · Cited by 70
Rueda, J., Realpe, T., Mejía, G. I., Zapata, E. M., Rozo, J. C., Ferro, B. E., & Robledo, J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01028-15 · Cited by 70
“Therefore, the cross-resistance between INH and ETH can be detected in Mycobacterium tuberculosis clinical isolates in the case of mutations affecting the common target, which may occur when patients have previously been treated with INH and not with ETH (5).”
BackgroundChollet, A., Maveyraud, L., Lherbet, C., & Bernardes‐Génisson, V. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.047 · Cited by 70
van Doorn, H. R., de Haas, P. E. W., Kremer, K., Vandenbroucke‐Grauls, C. M. J. E., Borgdorff, M. W., & van Soolingen, D. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01495.x · Cited by 66
“target of the active derivative of isoniazid [12].”
BackgroundAragón, L. M., Navarro, F., Heiser, V., Garrigó, M., Español, M., & Coll, P. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl058 · Cited by 71
“Mutations in the mabA-inhA regulatory region that exhibit both low-level isoniazid resistance and ethionamide resistance have been found in clinical isolates.(8,9) Less common, strains with mutations in the structural gene inhA have been described.”
Phosphorylation of InhA inhibits mycolic acid biosynthesis and growth of Mycobacterium tuberculosis
Molle, V., Gulten, G., Vilchèze, C., Veyron‐Churlet, R., Zanella‐Cléon, I., Sacchettini, J. C., Jacobs Jr, W. R., & Kremer, L. (2010) · Molecular Microbiology · doi:10.1111/j.1365-2958.2010.07446.x · Cited by 65
“smegmatis (Banerjee et al., 1994).”
BackgroundSelf-citationWarrier, T., Tropis, M., Werngren, J., Diehl, A., Gengenbacher, M., Schlegel, B., Schade, M., Oschkinat, H., Daffé, M., Hoffner, S., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05742-11 · Cited by 73
“Prominent first-line drugs against TB, such as isoniazid (INH) and ethambutol (EMB), target steps in mycolic acid and arabinogalactan synthesis, respectively (6, 47, 49).”
BackgroundUpare, A. A., Gadekar, P. K., Sivaramakrishnan, H., Naik, N. R., Khedkar, V. M., Sarkar, D. M., Choudhari, A. S., & Roopan, S. M. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.01.054 · Cited by 66
New horizons in the treatment of tuberculosis
Barry, C. E. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00163-9 · Cited by 73
Two Accessory Proteins Govern MmpL3 Mycolic Acid Transport in Mycobacteria
Fay, A., Czudnochowski, N., Rock, J. M., Johnson, J. R., Krogan, N. J., Rosenberg, O., & Glickman, M. S. (2019) · mBio · doi:10.1128/mbio.00850-19 · Cited by 65
“The enzymatic steps of the arabinogalactan and 66 mycolate precursor biosynthesis have been well described and are the targets of 67 several antimycobacterials, including isoniazid and ethambutol [1-3].”
BackgroundWheatley, R. W., Zheng, R. B., Richards, M. R., Lowary, T. L., & Ng, K. K. S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.347484 · Cited by 66
“Ethambutol inhibits at least one of the arabinosyltransferases responsible for arabinan formation (5), whereas isoniazid is a prodrug that targets an enoyl-acyl carrier protein reductase required for mycolic acid biosynthesis (6).”
BackgroundChallenges and Opportunities in Developing Novel Drugs for TB
Kaneko, T., Cooper, C. B., & Mdluli, K. E. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.115 · Cited by 74
Ghosh, A., Saran, N., & Saha, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-65766-8 · Cited by 69
Lety, M. A., Nair, S., Berche, P., & Escuyer, V (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.12.2629 · Cited by 65
“For example, resistance to isoniazid involves alterations in at least three distinct genes, katG, inhA, and ahpC (1, 32, 33, 35, 36).”
BackgroundThe quest for the holy grail: new antitubercular chemical entities, targets and strategies
Huszár, S., Chibale, K., & Singh, V. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.02.003 · Cited by 72
Comprehensive review on mechanism of action, resistance and evolution of antimycobacterial drugs
Chauhan, A., Kumar, M., Kumar, A., & Kanchan, K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119301 · Cited by 72
Discovery and Syntheses of “Superbug Challengers”—Platensimycin and Platencin
Palanichamy, K., & Kaliappan, K. P. (2010) · Chemistry - An Asian Journal · doi:10.1002/asia.200900423 · Cited by 65
Emerging therapeutic targets in tuberculosis: post-genomic era
Khasnobis, S., Escuyer, V. E., & Chatterjee, D. (2002) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.6.1.21 · Cited by 77
“Thus, the biosynthesis of mycolic acids involves four stages [45]: • firstly, the C24-C26 straight chain saturated fatty acids are formed that provide the C-1 and C-2 atoms leading to the formation of the α-alkyl branch of mycolic acid (presumably via fatty acid synthetase (FAS) I and FAS II) • secondly, the meromycol…”
BackgroundInfluentialWeinstein, E. A., Liu, L., Ordoñez, A. A., Wang, H., Hooker, J. M., Tonge, P. J., & Jain, S. K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01644-12 · Cited by 67
“Consensus holds that it is first oxidized by the mycobacterial catalaseperoxidase enzyme KatG and then conjugates with NAD (39, 42) to form an INH-NAD adduct that inhibits the enoyl-acyl carrier protein (enoyl-ACP) reductase InhA, among other targets (3, 27, 34, 39, 42).”
BackgroundMarimani, M. D., Ahmad, A., & Duse, A. G. (2018) · Tuberculosis · doi:10.1016/j.tube.2018.10.009 · Cited by 66
Current status and future development of antitubercular chemotherapy
Besra, G. S., & Kremer, L. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.8.1033 · Cited by 69
“ETH is reported to be bacteriostatic, although it is believed to have a mechanism of action similar to INH [5,11,15].”
BackgroundBang, D., Andersen, Å. B., & Thomsen, V. Ø. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00752-06 · Cited by 63
“INH resistance has been associated mainly with mutations in katG, inhA, ahpC, and kasA (2, 13, 15, 18).”
BackgroundTukvadze, N., Kempker, R. R., Kalandadze, I., Kurbatova, E. V., Leonard, M. K., Jr., Apsindzelashvili, R., Bablishvili, N., Kipiani, M., & Blumberg, H. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031563 · Cited by 63
“Additionally, ethionamide inhibits InhA [24], and as our results demonstrate, if InhA mutations are present ethionamide resistance is highly likely.”
ResultInfluentialNew insights into pathways for CD1-mediated antigen presentation
Sugita, M., Cernadas, M., & Brenner, M. B. (2003) · Current Opinion in Immunology · doi:10.1016/j.coi.2003.11.014 · Cited by 70
Brown, A. K., Bhatt, A., Singh, A., Saparia, E., Evans, A. F., & Besra, G. S. (2007) · Microbiology · doi:10.1099/mic.0.2007/012419-0 · Cited by 63
“Purification and biochemical characterization of the Mycobacterium tuberculosis b-ketoacyl-acyl carrier protein synthases KasA and KasB.”
InfluentialManagement of Multidrug-Resistant Tuberculosis
Caminero, J. A., & Daley, C. L. (2018) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0038-1661383 · Cited by 67
Antitubercular Isoniazid and Drug Resistance of Mycobacterium tuberculosis — A Review
Scior, T., Morales, I. M., Garcés‐Eisele, S. J., Domeyer, D. M., & Laufer, S. (2002) · Archiv der Pharmazie · doi:10.1002/ardp.200290005 · Cited by 66
Ducasse-Cabanot, S., Cohen‐Gonsaud, M., Marrakchi, H., Nguyen, M., Zerbib, D., Bernadou, J., Daffé, M., Labesse, G., & Quémard, A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.242-249.2004 · Cited by 76
“tuberculosis (2, 18), by covalently binding to its cofactor, NADH, forming an isonicotinoyl-NAD adduct (19, 25, 31).”
BackgroundPanas, M. W., Jain, P., Yang, H., Mitra, S., Biswas, D., Wattam, A. R., Letvin, N. L., & Jacobs, W. R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414207111 · Cited by 62
Self-citationStigliani, J.-L., Bernardes-Génisson, V., Bernadou, J., & Pratviel, G. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob25602a · Cited by 62
Levy, C., Baldock, C., Wallace, A. J., Sedelnikova, S. E., Viner, R. C., Clough, J. M., Stuitje, A. R., Slabas, A. R., Rice, D. W., & Rafferty, J. B. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4643 · Cited by 62
Dias, M. V. B., Vasconcelos, I. B., Prado, A. M. X., Fadel, V., Basso, L. A., de Azevedo, W. F., & Santos, D. S. (2007) · Journal of Structural Biology · doi:10.1016/j.jsb.2007.04.009 · Cited by 75
Spagnuolo, L. A., Eltschkner, S., Yu, W., Daryaee, F., Davoodi, S., Knudson, S. E., Allen, E. K. H., Merino, J., Pschibul, A., Moree, B., et al. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b11148 · Cited by 64
Molecular action of anti-mycobacterial agents
Chopra, I., & Brennan, P. J. (1998) · Tubercle and Lung Disease · doi:10.1016/s0962-8479(98)80001-4 · Cited by 77
Sharma, A., Rosa, M. D., Singla, N., Singh, G., Barnwal, R. P., & Pandey, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01833 · Cited by 64
Cantaloube, S., Veyron‐Churlet, R., Haddache, N., Daffé, M., & Zerbib, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029564 · Cited by 74
“After reduction by the keto-acyl-ACP reductase (KR) MabA [19,20,21], then dehydration by the recently identified hetero-dimers HadAB and HadBC hydroxylacyl-dehydratase (DH) [22,23,24] and finally the reduction by the enoyl-ACP reductase (ER) InhA [25], the fully saturated acylchain enter into a new cycle of elongation…”
BackgroundInfluentialDaniel, J., Oh, T., Lee, C., & Kolattukudy, P. E. (2006) · Journal of Bacteriology · doi:10.1128/jb.01019-06 · Cited by 66
“More recent work has shown that the reductases are the targets of isoniazid inhibition in M. tuberculosis ( 1 , 25).”
BackgroundAntibiotic resistance genes in the Actinobacteria phylum
Bafghi, M. F. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03580-5 · Cited by 69
Antibiotics and resistance: the two-sided coin of the mycobacterial cell wall
Batt, S. M., Burke, C., Moorey, A. R., & Besra, G. S. (2020) · The Cell Surface · doi:10.1016/j.tcsw.2020.100044 · Cited by 80
Pereiro, J. E., Sánchez‐Montalvá, A., Aznar, M. L., & Espiau, M. (2022) · Medicina · doi:10.3390/medicina58020188 · Cited by 76
“BDQ: bedaquiline, AMK: amikacin, DLM: delamanid, Km: kanamycin, Mfx: moxifloxacin, CFZ: clofazimine, ETO: ethionamid, Z: pyraizinamid, E: ethambutol, INH: isonizid, TB: tuberculosis, HIV: human immunodeficiency virus, LZD: linezolid.”
BackgroundInfluentialRole of Superoxide in Catalase-Peroxidase-Mediated Isoniazid Action against Mycobacteria
Wang, J., Burger, R. M., & Drlica, K. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.709 · Cited by 60
Paediatric use of second-line anti-tuberculosis agents: A review
Seddon, J. A., Hesseling, A. C., Marais, B. J., McIlleron, H., Peloquin, C. A., Donald, P. R., & Schaaf, H. S. (2011) · Tuberculosis · doi:10.1016/j.tube.2011.11.001 · Cited by 61
Diversity and evolution of drug resistance mechanisms in Mycobacterium tuberculosis
Al-Saeedi, M., & Al‐Hajoj, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s144446 · Cited by 61
“60 Furthermore, arabi-nosyl transferases (which link peptidoglycan with an outer mycolic acid layer to form the mycolyl-arabinogalactan–peptidoglycan complex) may be a target for EMB, a drug that inhibits arabinosyl transferase activity and causes increased cell wall permeability.”
van Doorn, H. R., Claas, E. C. J., Templeton, K. E., van der Zanden, A. G. M., Vije, A. T. K., de Jong, M. D., Dankert, J., & Kuijper, E. J. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.10.4630-4635.2003 · Cited by 61
“tase (3), which is part of the fatty acid synthase II (FAS II)”
Background
Metadata
- Authors
- Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R.
- Affiliations
- Albert Einstein College of Medicine (US)
- Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY 10461.
- AgResearch (NZ)
- AgResearch, Wallaceville Animal Research Center, Upper Hutt, New Zealand.
- Venue
- Science
- Published
- 1994-01-14
- Volume
- 263
- Issue
- 5144
- Pages
- 227-230
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2075000963
- Cited by
- 1,389
- References
- 46
- Citations by year
- 2026: 24 · 2025: 32 · 2024: 31 · 2023: 43 · 2022: 49 · 2021: 39 · 2020: 45 · 2019: 52 · 2018: 52 · 2017: 62 · 2016: 45 · 2015: 54 · 2014: 69 · 2013: 39 · 2012: 57
- FWCI
- 46.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u01ai030189-03)
- National Institute of Allergy and Infectious Diseases (AI 27160, UO1AI30189)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Keywords
- inhA gene, isoniazid, ethionamide, Mycobacterium tuberculosis, therapeutic target, drug resistance, missense mutations, mycolic acid biosynthesis, Mycobacterium smegmatis, Mycobacterium bovis BCG, antitubercular agents
- MeSH terms
- Amino Acid Sequence, Bacterial Proteins, Base Sequence, Cloning, Molecular, Drug Resistance, Microbial, Ethionamide, Genes, Bacterial, Isoniazid, Molecular Sequence Data, Mutation, Mycobacterium, Mycobacterium bovis, Mycobacterium tuberculosis, Mycolic Acids, Oxidoreductases, Open Reading Frames, Sequence Alignment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.